-
Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone Lancet Oncol. (IF 41.6) Pub Date : 2024-07-25 F Anthony Greco, Chris Labaki, Elie Rassy
-
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial Lancet Oncol. (IF 41.6) Pub Date : 2024-07-25 Xin Liu MD, Xiaowei Zhang MD, Shiyu Jiang MD, Miao Mo MM, Qifeng Wang MD, Yanli Wang MM, Liangping Zhou MD, Silong Hu MD, Prof Huijuan Yang MD PhD, Yifeng Hou MD, Prof Yong Chen MD, Xueguan Lu MD, Yu Wang MD, Prof Xiaoyan Zhou MD, Wentao Li MD, Prof Cai Chang MD, Xiujiang Yang MD, Ke Chen MD, Jun Cao MD, Qinghua Xu PhD, Yifeng Sun MSc, Jianfeng Luo MD PhD, Zhiguo Luo MD, Prof Xichun Hu MD PhD
Empirical chemotherapy remains the standard of care in patients with unfavourable cancer of unknown primary (CUP). Gene-expression profiling assays have been developed to identify the tissue of origin in patients with CUP; however, their clinical benefit has not yet been demonstrated. We aimed to evaluate the efficacy and safety of site-specific therapy directed by a 90-gene expression assay compared
-
Impact of pharmacy benefit managers on cancer health care Lancet Oncol. (IF 41.6) Pub Date : 2024-07-18 Priya Venkatesan
-
Call for stricter tobacco control laws in Ghana Lancet Oncol. (IF 41.6) Pub Date : 2024-07-18 Manjulika Das
-
Lifestyle factors driving cancer cases and mortality in the USA Lancet Oncol. (IF 41.6) Pub Date : 2024-07-18 Karl Gruber
-
Alleviating retroperitoneal pain with celiac plexus radiosurgery Lancet Oncol. (IF 41.6) Pub Date : 2024-07-16 Daniel Moore-Palhares, Sylvia S W Ng, Alexander V Louie
-
Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-07-16 Yaacov R Lawrence MBBS FASTRO, Marcin Miszczyk MD PhD, Laura A Dawson MD, Dayssy Alexandra Diaz Pardo MD, Artur Aguiar MD, Dror Limon MD, Raphael M Pfeffer MBBS, Michael Buckstein MD PhD, Prof Aisling S Barry MB BCh, Tikva Meron PhD, Prof Adam P Dicker MD PhD, Jerzy Wydmański MD PhD, Camilla Zimmermann MD PhD, Ofer Margalit MD PhD, David Hausner MD, Ofir Morag MD, Prof Talia Golan MD, Galia Jacobson
Refractory upper abdominal pain or lower back pain (retroperitoneal pain syndrome) related to celiac plexus involvement characterises pancreatic and other upper gastrointestinal malignancies and is an unmet need. We hypothesised that ablative radiation delivered to the celiac plexus would decrease pain. This multicentre, single-arm, phase 2 study was done at eight hospitals in five countries (Israel
-
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study Lancet Oncol. (IF 41.6) Pub Date : 2024-07-15 Guihong Wan PhD, Wenxin Chen MBI, Sara Khattab BS, Katie Roster MS, Nga Nguyen MD, Boshen Yan MBI, Ahmad Rajeh MS, Jayhyun Seo BA, Hannah Rashdan BS, Leyre Zubiri MD PhD, Matthew J Hadfield DO, Shadmehr Demehri MD PhD, Kun-Hsing Yu MD PhD, William Lotter PhD, Alexander Gusev PhD, Nicole R LeBoeuf MD, Kerry L Reynolds MD, Shawn G Kwatra MD, Yevgeniy R Semenov MD MA
Understanding co-occurrence patterns and prognostic implications of immune-related adverse events is crucial for immunotherapy management. However, previous studies have been limited by sample size and generalisability. In this study, we leveraged a multi-institutional cohort and a population-level database to investigate co-occurrence patterns of and survival outcomes after multi-organ immune-related
-
Leaked documents suggest Philip Morris International's link to research activities Lancet Oncol. (IF 41.6) Pub Date : 2024-07-14 Talha Burki
-
Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis Lancet Oncol. (IF 41.6) Pub Date : 2024-07-11 Kristina Jenei BSN, Arianna Gentilini MSc, Alyson Haslam PhD, Prof Vinay Prasad MD
Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in the USA, Canada, Australia, UK, Israel, Brazil, Singapore, and Switzerland to bring promising cancer drugs to patients earlier. We explored the clinical benefit, time to regulatory approval and health technology assessment recommendations, reimbursement outcomes, and monthly treatment
-
NHS cancer services and systems—ten pressure points a UK cancer control plan needs to address Lancet Oncol. (IF 41.6) Pub Date : 2024-07-08 Prof Ajay Aggarwal PhD, Prof Richard Simcock MD, Prof Pat Price MD, Prof Bernard Rachet PhD, Prof Georgios Lyratzopoulos MD, Prof Kate Walker PhD, Katie Spencer PhD, Tom Roques MD, Prof Richard Sullivan PhD
In this Policy Review we discuss ten key pressure points in the NHS in the delivery of cancer care services that need to be urgently addressed by a comprehensive national cancer control plan. These pressure points cover areas such as increasing workforce capacity and its productivity, delivering effective cancer survivorship services, addressing variation in quality, fixing the reimbursement system
-
Carcinogenicity of talc and acrylonitrile Lancet Oncol. (IF 41.6) Pub Date : 2024-07-05 Leslie T Stayner, Tania Carreón-Valencia, Paul A Demers, Jason M Fritz, Malcolm R Sim, Patricia Stewart, Hiroyuki Tsuda, Andres Cardenas, Dario Consonni, Laurie Davies, Sara De Matteis, Emanuela Felley-Bosco, Andrew J Ghio, Thomas Göen, Yann Grosse, Alessandro F Gualtieri, P David Josephy, Stella Koutros, Igor Linhart, Henriqueta Louro, Katie M O'Brien, Simona Panzacchi, Laura Peña, Pavel Rössner,
-
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study Lancet Oncol. (IF 41.6) Pub Date : 2024-07-05 Prof Dimitris Bertsimas PhD, Georgios Antonios Margonis MD PhD, Suleeporn Sujichantararat PhD, Angelos Koulouras BSc, Yu Ma BSc, Prof Cristina R Antonescu MD, Prof Murray F Brennan MD, Prof Javier Martín-Broto MD, Seehanah Tang BSc, Prof Piotr Rutkowski MD PhD, Prof Martin E Kreis MD, Prof Katharina Beyer MD, Jane Wang MD, Elzbieta Bylina MD PhD, Pawel Sobczuk MD PhD, Antonio Gutierrez MD PhD, Bhumika
Current guidelines recommend use of adjuvant imatinib therapy for many patients with gastrointestinal stromal tumours (GISTs); however, its optimal treatment duration is unknown and some patient groups do not benefit from the therapy. We aimed to apply state-of-the-art, interpretable artificial intelligence (ie, predictions or prescription logic that can be easily understood) methods on real-world
-
ESMO Gastrointestinal Cancers Congress 2024 Lancet Oncol. (IF 41.6) Pub Date : 2024-07-04 Katherine Gourd
-
New report from STRONG-AYA on addressing needs of adolescents and young adults with cancer in Europe Lancet Oncol. (IF 41.6) Pub Date : 2024-07-04 Manjulika Das
-
Nigeria mandates reporting of all cancer diagnoses Lancet Oncol. (IF 41.6) Pub Date : 2024-07-04 Paul Adepoju
-
Cancer and premature mortality—pushing the frontiers of cancer care Lancet Oncol. (IF 41.6) Pub Date : 2024-07-01 Andrew Toyin Olagunju
-
Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000–19: a retrospective, cross-sectional, population-based study Lancet Oncol. (IF 41.6) Pub Date : 2024-07-01 Shilpa S Murthy MD MPH, Dario Trapani MD, Bochen Cao PhD, Freddie Bray PhD, Shashanka Murthy BS, Prof Thomas Peter Kingham MD, Prof Chandrakanth Are MBBS MBA, André M Ilbawi MD
Cancer is a leading cause of mortality worldwide. By 2040, over 30 million new cancers are predicted, with the greatest cancer burden in low-income countries. In 2015, the UN passed the Sustainable Development Goal 3.4 (SDG 3.4) to tackle the rising burden of non-communicable diseases, which calls for a reduction by a third in premature mortality from non-communicable diseases, including cancer, by
-
ImmunoPET in high-grade neuroendocrine tumours Lancet Oncol. (IF 41.6) Pub Date : 2024-06-28 Francesco Giammarile, Roberto C Delgado Bolton, Fuad Novruzov, Diana Paez
-
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial Lancet Oncol. (IF 41.6) Pub Date : 2024-06-28 Salomon Tendler MD, Mark P Dunphy DO, Matthew Agee MD, Joseph O'Donoghue PhD, Rania G Aly MD, Noura J Choudhury MD, Adam Kesner PhD, Prof Assen Kirov PhD, Audrey Mauguen PhD, Marina K Baine MD, Prof Heiko Schoder MD, Prof Wolfgang A Weber MD, Prof Natasha Rekhtman MD, Prof Serge K Lyashchenko PhD, Prof Lisa Bodei MD, Prof Michael J Morris MD, Prof Jason S Lewis PhD, Prof Charles M Rudin MD, John T
Delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of small-cell lung cancer (SCLC) and neuroendocrine prostate cancer cells. We assessed the safety and feasibility of the DLL3-targeted imaging tracer [Zr]Zr-DFO-SC16.56 (composed of the anti-DLL3 antibody SC16.56 conjugated to p-SCN-Bn-deferoxamine [DFO] serving as a chelator for zirconium-89) in patients with neuroendocrine-derived
-
New Zealand expands cancer treatment with funding boost Lancet Oncol. (IF 41.6) Pub Date : 2024-06-27 Paul Adepoju
-
Closing the research gaps in obstetric health for survivors of cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-06-26 Ranjeet Bajpai, Jyoti Bajpai
-
Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study Lancet Oncol. (IF 41.6) Pub Date : 2024-06-26 Ceren Sunguc PhD, David L Winter HNC, Emma J Heymer PhD, Gavin Rudge MSc, Angela Polanco PhD, Katherine A Birchenall PhD, Melanie Griffin MD, Prof Richard A Anderson MD, Prof W Hamish B Wallace MD, Prof Michael M Hawkins DPhil, Raoul C Reulen PhD
There are limited data on the risks of obstetric complications among survivors of adolescent and young adult cancer with most previous studies only reporting risks for all types of cancers combined. The aim of this study was to quantify deficits in birth rates and risks of obstetric complications for female survivors of 17 specific types of adolescent and young adult cancer. The Teenage and Young Adult
-
Perioperative immunotherapy in renal cell carcinoma Lancet Oncol. (IF 41.6) Pub Date : 2024-06-25 Delphine Borchiellini, Karim Bensalah
-
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study Lancet Oncol. (IF 41.6) Pub Date : 2024-06-25 Prof Mohamad E Allaf MD, Se-Eun Kim MB, Prof Viraj Master MD, Prof David F McDermott MD, Lauren C Harshman MD, Suzanne M Cole MD, Prof Charles G Drake MD, Prof Sabina Signoretti MD, Mahmut Akgul MD, Nicholas Baniak MD, Elsa Li-Ning MD, Matthew B Palmer MD, Hamid Emamekhoo MD, Nabil Adra MD, Hristos Kaimakliotis MD, Yasser Ged MBBS, Prof Phillip M Pierorazio MD, Prof E Jason Abel MD, Mehmet A Bilen
The standard of care for patients with intermediate-to-high risk renal cell carcinoma is partial or radical nephrectomy followed by surveillance. We aimed to investigate use of nivolumab before nephrectomy followed by adjuvant nivolumab in patients with high-risk renal cell carcinoma to determine recurrence-free survival compared with surgery only. In this open-label, randomised, phase 3 trial (PROSPER
-
More needed to improve early cancer diagnosis Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 The Lancet Oncology
-
Dual therapy in metastatic castration-resistant prostate cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Jiaqi Huang, Fei Leng
-
Overcoming barriers to early breast cancer presentation in Nigeria Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Mercy Ofuya
-
Randomised trials in children with rhabdomyosarcoma: time for a change? Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Ewa Koscielniak, Thomas Klingebiel
-
Painful annular skin rash on both legs in a patient with rectal cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Han-Wen Lin MD, Chun-Yu Cheng MD
-
CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Anna-Maria Lazaratos, Kevin Petrecca, Marie-Christine Guiot, Katarzyna J Jerzak, Matthew Dankner
-
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Prof Abha A Gupta MD, Wei Xue PhD, Douglas J Harrison MD, Prof Douglas S Hawkins MD, Prof Roshni Dasgupta MD, Prof Suzanne Wolden MD, Barry Shulkin MD, Amira Qumseya MSc, Jonathan C Routh MD, Tamara MacDonald PharmD, Shari Feinberg NP, Brian Crompton MD, Prof Erin R Rudzinski MD, Michael Arnold MD, Prof Raj Venkatramani MD
The Children's Oncology Group defines intermediate-risk rhabdomyosarcoma as unresected fusion-negative disease arising at an unfavourable site or non-metastatic fusion-positive disease. Temsirolimus in combination with chemotherapy has shown promising activity in patients with relapsed or refractory rhabdomyosarcoma. We aimed to compare event-free survival in patients with intermediate-risk rhabdomyosarcoma
-
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Selim Corbacioglu MD PhD, Holger Lode MD PhD, Susanne Ellinger MSc, Florian Zeman MSc, Meinolf Suttorp MD PhD, Gabriele Escherich MD, Konrad Bochennek MD, Bernd Gruhn MD, Peter Lang MD, Marius Rohde MD, Klaus Michael Debatin MD PhD, Daniel Steinbach MD, Andreas Beilken MD, Ruth Ladenstein MD, Rainer Spachtholz MSc, Peter Heiss MD, Dirk Hellwig MD PhD, Anja Tröger MD PhD, Michael Koller PhD, Karin Menhart
Neuroblastoma is the most common extracranial solid tumour in children. Relapsed or refractory neuroblastoma is associated with a poor outcome. We assessed the combination of irinotecan–temozolomide and dasatinib–rapamycin (RIST) in patients with relapsed or refractory neuroblastoma. The multicentre, open-label, randomised, controlled, phase 2, RIST-rNB-2011 trial recruited from 40 paediatric oncology
-
Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Fengyi Jin PhD, Prof Claire M Vajdic PhD, I Mary Poynten PhD, Jennifer K McGee-Avila PhD, Prof Philip E Castle PhD, Prof Andrew E Grulich PhD
Systematic evaluations of cancer risk in people living with HIV or AIDS (PLHIV) and solid organ transplant recipients provide unique insights into the role of the immune system in cancer development. In this systematic review and meta-analysis, we expand previous analyses of cancer risk for these two immunocompromised populations. We considered studies published in English and listed on PubMed or Embase
-
-
Olufunmilayo Olopade—preventive oncologist using genetics to fight breast cancer in high-risk populations Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Elizabeth Gourd
-
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Ahmad K Abou-Foul MD, Christina Henson MD, Prof Rebecca D Chernock MD, Shao Hui Huang MD, William M Lydiatt MD, Lachlan McDowell MBBS, Prof Brian O’Sullivan MD, Bayardo Perez-Ordonez MD, Prof Max Robinson PhD, Paul C Nankivell PhD, Elena Ruiz-Bravo MD, Simion I Chiosea MD, Tina M Green PhD, Prof Keith D Hunter FRCPath, Jacqueline SG Hwang FRCPA, Prof Senada Koljenovic PhD, Sjors A Koppes PhD, Stine
Detection of extranodal extension on histopathology in surgically treated head and neck squamous cell carcinoma indicates poor prognosis. However, there is no consensus on the diagnostic criteria, interpretation, and reporting of histology detected extranodal extension, which has contributed to conflicting evidence in the literature, and likely clinical inconsistency. The Head and Neck Cancer International
-
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Annette M Lim PhD, Prof Christophe Le Tourneau MD, Chris Hurt MSc, Prof Sarbani G Laskar MD, Conor E Steuer MD, Velda L Y Chow FCSHK, Petr Szturz PhD, Christina Henson MD, Andrew T Day MD, James E Bates MD, Smaro Lazarakis BEd[Sec]-Lib, Lachlan McDowell FRANZCR, Prof Hisham Mehanna PhD, Prof Sue S Yom PhD, the HNCIG
Transparent and precise endpoint definitions are a crucial aspect of clinical trial conduct and reporting, and are used to communicate the benefit of an intervention. Previous studies have identified inconsistencies in endpoint definitions across oncological clinical trials. Here, the Head and Neck Cancer International Group assessed endpoint definitions from phase 3 trials or trials considered practice-changing
-
Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Annette M Lim PhD, Lachlan McDowell FRANZCR, Chris Hurt MSc, Prof Christophe Le Tourneau MD, Akihiro Homma PhD, George Shenouda FRCP, Prof David J Thomson MD, Prof Antoine Moya-Plana PhD, Christina Henson MD, Petr Szturz PhD, Andrew T Day MD, James E Bates MD, Smaro Lazarakis BEd[Sec]-Lib, Prof Juliette Thariat PhD, Prof Amanda Psyrri MD, Prof Hisham Mehanna PhD, Prof Sue S Yom PhD, the HNCIG
Robust time-to-event endpoint definitions are crucial for the assessment of treatment effect and the clinical value of trial interventions. Here, the Head and Neck Cancer International Group investigated endpoint use in phase 3 trials and trials considered potentially practice-changing published between 2008 and 2021 in the curative-intent setting for patients with mucosal head and neck squamous cell
-
Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations Lancet Oncol. (IF 41.6) Pub Date : 2024-06-24 Christina Henson MD, Ahmad K Abou-Foul MD, Eugene Yu MD, Christine Glastonbury MBBS, Shao Hui Huang MD, Ann D King FRCR, William M Lydiatt MD, Lachlan McDowell MBBS, Alex A Nagelschneider MD, Paul C Nankivell PhD, Prof Brian O’Sullivan MD, Rhian Rhys FRCR, Youping Xiao, David Andrew PhD, Jon T Asmussen MD, Francois Bidault MD PhD, Jan W Dankbaar PhD, Pim de Graaf MD PhD, Eloisa S Gebrim MD PhD, Chaosu
Extranodal extension of tumour on histopathology is known to be a negative prognostic factor in head and neck cancer. Compelling evidence suggests that extranodal extension detected on radiological imaging is also a negative prognostic factor. Furthermore, if imaging detected extranodal extension could be identified reliably before the start of treatment, it could be used to guide treatment selection
-
Cancer priorities set out in manifestos as organisations warn of worsening standards Lancet Oncol. (IF 41.6) Pub Date : 2024-06-20 Emma Wilkinson
-
Daratumumab maintenance in patients with myeloma Lancet Oncol. (IF 41.6) Pub Date : 2024-06-15 Meral Beksac
-
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-06-15 Prof Philippe Moreau MD, Cyrille Hulin MD, Aurore Perrot MD, Bertrand Arnulf MD, Karim Belhadj MD, Lotfi Benboubker MD, Prof Sonja Zweegman MD, Hélène Caillon PharmD, Denis Caillot MD, Prof Hervé Avet-Loiseau MD, Prof Michel Delforge MD, Thomas Dejoie PharmD, Prof Thierry Facon MD, Cécile Sonntag MD, Jean Fontan MD, Mohamad Mohty MD, Kon-Siong Jie MD, Lionel Karlin MD, Frédérique Kuhnowski MD, Jérôme
CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone as an induction and consolidation regimen in transplant-eligible patients newly diagnosed with myeloma. In CASSIOPEIA part 2, daratumumab maintenance significantly
-
Four industries responsible for millions of deaths each year Lancet Oncol. (IF 41.6) Pub Date : 2024-06-13 Talha Burki
-
Artificial intelligence for scoring prostate MRI: ready for prospective evaluation Lancet Oncol. (IF 41.6) Pub Date : 2024-06-11 Martin Eklund
-
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study Lancet Oncol. (IF 41.6) Pub Date : 2024-06-11 Anindo Saha MSc, Joeran S Bosma MSc, Jasper J Twilt MSc, Prof Bram van Ginneken PhD, Prof Anders Bjartell MD, Prof Anwar R Padhani MD, Prof David Bonekamp MD, Prof Geert Villeirs MD, Prof Georg Salomon MD, Prof Gianluca Giannarini MD, Prof Jayashree Kalpathy-Cramer PhD, Prof Jelle Barentsz MD, Prof Klaus H Maier-Hein PhD, Mirabela Rusu PhD, Prof Olivier Rouvière MD, Roderick van den Bergh MD, Prof
Artificial intelligence (AI) systems can potentially aid the diagnostic pathway of prostate cancer by alleviating the increasing workload, preventing overdiagnosis, and reducing the dependence on experienced radiologists. We aimed to investigate the performance of AI systems at detecting clinically significant prostate cancer on MRI in comparison with radiologists using the Prostate Imaging—Reporting
-
Cancer updates from the 77th World Health Assembly Lancet Oncol. (IF 41.6) Pub Date : 2024-06-06 Paul Adepoju
-
UK NHS to enrol thousands in trials of personalised mRNA cancer vaccines Lancet Oncol. (IF 41.6) Pub Date : 2024-06-06 Tony Kirby
-
New Canadian draft breast screening guidelines issued Lancet Oncol. (IF 41.6) Pub Date : 2024-06-06 Renée Pellerin
-
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study Lancet Oncol. (IF 41.6) Pub Date : 2024-06-06 Jie-Hai Yu MD, Bin-Yi Xiao MD, Dan-Dan Li MD, Wu Jiang MD, Ya Ding MD, Xiao-Jun Wu MD, Rong-Xin Zhang MD, Jun-Zhong Lin MD, Wei Wang MD, Kai Han MD, Ling-Heng Kong MD, Xin-Ke Zhang MD, Bi-Yun Chen, Wei-Jian Mei MD, Zhi-Zhong Pan MD, Jing-Hua Tang MD, Xiao-Shi Zhang MD, Prof Pei-Rong Ding MD
PD-1 blockade is highly efficacious for mismatch repair-deficient colorectal cancer in both metastatic and neoadjuvant settings. We aimed to explore the activity and safety of neoadjuvant therapy with PD-1 blockade plus an angiogenesis inhibitor and the feasibility of organ preservation in patients with locally advanced mismatch repair-deficient colorectal cancer. We initiated a single-arm, open-label
-
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-06-05 Prof Douglas Adkins MD, Jessica C Ley BS, Jingxia Liu PhD, Peter Oppelt MD
VEGF, a key mediator of angiogenesis and resistance to immunotherapy, is overexpressed in head and neck squamous cell carcinoma (HNSCC). We aimed to determine the recommended phase 2 dose of ramucirumab, a selective VEGFR2 inhibitor, given with pembrolizumab and the objective response rate of this combination as first-line treatment for recurrent or metastatic HNSCC. In this single-centre, phase 1/2
-
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care Lancet Oncol. (IF 41.6) Pub Date : 2024-06-04 Anna Dowrick PhD, Prof Sue Ziebland MA, Tanvi Rai PhD, Claire Friedemann Smith DPhil, Brian D Nicholson DPhil
Improving cancer outcomes through innovative cancer detection initiatives in primary care is an international policy priority. There are unique implementation challenges to the roll-out and scale-up of different innovations, requiring synchronisation between national policy levers and local implementation strategies. We draw on implementation science to highlight key considerations when seeking to
-
Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial Lancet Oncol. (IF 41.6) Pub Date : 2024-06-04 Marjorie G Zauderer, Ibiayi Dagogo-Jack
-
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study Lancet Oncol. (IF 41.6) Pub Date : 2024-06-04 Prof Joachim G Aerts MD PhD, Robert Belderbos MD, Prof Paul Baas MD PhD, Prof Arnaud Scherpereel MD, Koen Bezemer Bsc, Ilona Enninga PhD, Rob Meijer MSc, Marcella Willemsen PhD, Prof Rossana Berardi MD, Prof Dean Fennell MD, Rene Kerstens Bsc, Robin Cornelissen MD PhD, Prof Jan P van Meerbeeck MD, DENIM team
Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We aimed to establish the efficacy of dendritic cells loaded with allogeneic tumour cell lysate (MesoPher, Amphera BV, 's-Hertogenbosch, Netherlands) as maintenance therapy in patients with pleural mesothelioma. In this open-label, randomised, phase 2/3 study, patients with histologically confirmed unresectable
-
Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-06-01 Priyadarshini Pathak, Colin Weekes, Jennifer Y Wo
-
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study Lancet Oncol. (IF 41.6) Pub Date : 2024-06-01 Prof Jean-Luc Van Laethem MD, Prof Ivan Borbath MD, Prof Hans Prenen MD, Prof Karen Paula Geboes MD, Aurélien Lambert MD, Emmanuel Mitry MD, Philippe Alexandre Cassier MD, Prof Jean-Frédéric Blanc MD, Lorenzo Pilla MD, Jaime Feliu Batlle MD, Mercedes Rodriguez Garrote MD, Roberto Antonio Pazo-Cid MD, Inmaculada Gallego MD, Karin Enell Smith PhD, Peter Ellmark PhD, Yago Pico de Coaña PhD, Sumeet Vijay
Current systemic therapies for metastatic pancreatic ductal adenocarcinoma are associated with poor outcomes with a 5-year overall survival rate under 5%. We aimed to assess the safety and antitumour activity of mitazalimab, a human CD40 agonistic IgG1 antibody, with modified FOLFIRINOX (mFOLFIRINOX; fluorouracil, leucovorin, oxaliplatin, and irinotecan), in chemotherapy-naive patients with metastatic
-
Tobacco and e-cigarette use in young people: an ongoing challenge Lancet Oncol. (IF 41.6) Pub Date : 2024-05-31 Talha Burki
-
Can a Major Conditions Strategy substitute for a National Cancer Control Plan? Lancet Oncol. (IF 41.6) Pub Date : 2024-05-30 Ajay Aggarwal, Richard Sullivan
-
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study Lancet Oncol. (IF 41.6) Pub Date : 2024-05-29 Yuxiang Ma MD, Yan Huang MD, Yuanyuan Zhao MD, Shen Zhao MD, Jinhui Xue MD, Yunpeng Yang MD, Wenfeng Fang MD, Prof Ye Guo MD, Yaqian Han MD, Kunyu Yang MD, Yongsheng Li MD, Jun Yang MD, Zhenming Fu MD, Gang Chen MD, Likun Chen MD, Ningning Zhou MD, Ting Zhou MD, Yaxiong Zhang MD, Prof Huaqiang Zhou MD, Qianwen Liu MD, Yi Zhu PhD, Hai Zhu PhD, Sa Xiao PhD, Prof Li Zhang MD, Prof Hongyun Zhao MD
Antibody–drug conjugates have promising clinical activity in the treatment of solid tumours. BL-B01D1 is a first-in-class EGFR–HER3 bispecific antibody–drug conjugate. We aimed to assess the safety and preliminary antitumour activity of BL-B01D1 in patients with locally advanced or metastatic solid tumours. This first-in-human, open-label, multicentre, dose-escalation and dose-expansion phase 1 trial
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee Lancet Oncol. (IF 41.6) Pub Date : 2024-05-28 Prof Yi Lin MD PhD, Prof Lugui Qiu MD, Prof Saad Usmani MD MBA, Prof Chng Wee Joo MD, Prof Luciano Costa MD PhD, Benjamin Derman MD, Prof Juan Du MD PhD, Prof Hermann Einsele MD FRCP, Prof Carlos Fernandez de Larrea MD PhD, Prof Roman Hajek MD PhD, Prof P Joy Ho, Efstathios Kastritis MD, Joaquin Martinez-Lopez, Prof Maria-Victoria Mateos MD PhD, Prof Joseph Mikhael MD, Prof Philippe Moreau MD, Chandramouli
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only)